Busby Pharma Consulting, LLC
A Specialist for Clinical Success

Successful medical innovations in recent years have fueled notable improvements in healthcare outcomes. Yet, advancing a new drug from the IND stage through clinical trials, and ultimately into the market, remains complex. The intricate drug development process demands meticulous preparation and optimal resource allocation to yield effective outcomes. Particularly for smaller companies with constrained budgets, the recent funding crunch has accentuated the importance of astute strategic planning.

A guiding light in the pharmaceutical industry, Busby Pharma Consulting (BPC) specializes in assisting companies transitioning from drug discovery to development.

With a focus on strategic IND planning, BPC offers a comprehensive range of services that cover critical aspects of drug development. BPC guides companies through the winding trajectory of early-stage research, progressing from proof of concept in the laboratory to clinical validation in patients and post-marketing endeavors.

“We provide a fit-for-purpose approach to discovery and early development needs of small companies, offering strategic and operational consulting services tailored to their unique situation,” says Dr. Robert W. Busby, president of Busby Pharma Consulting.

Dr. Busby brings profound industry knowledge to provide informed strategic guidance across all drug development stages, from preliminary screening to post-approval. Leveraging his expertise in pharmacology, pharmacokinetics, drug metabolism, clinical pharmacology, and bioanalytical support, he has tailored optimal strategies for over 30 clients in a span of nine years.

A White-Glove Approach to the IND Process

Busby Pharma Consulting caters primarily to smaller companies operating with constrained budgets, where strategic decision-making is paramount for judicious allocation of funds. This is of critical importance now, as venture capitalists have become more cautious when investing in biotech projects. Smaller players are forced to choose between advancing multiple programs to major milestones or focusing on fewer programs and making them financially viable.

Its overarching goal is to streamline the drug development process for small companies, ensuring swift progress while minimizing expenditures; an approach that is the cornerstone of the consultancy’s services.

To maintain a deft balance between expediting the path to proof of concept and maintaining cost efficiency, BPC advocates for timely expenditures while avoiding premature financial commitments. Through optimization of available resources, BPC enables clients to achieve critical milestones like proper IND planning by obtaining essential scientific data and ensuring compliance with regulatory requirements, helping them to efficiently progress through the different phases of clinical trials.

Central to Busby Pharma Consulting’s value proposition is its ability to customize IND activities to harmonize with the distinct circumstances of each client. Leveraging a specialization in pharmacokinetics, hit-to-lead studies, and lead optimization, BPC excels at designing high throughput assays, choosing suitable secondary assays, and integrating drug-like property assays to pinpoint promising lead compounds.

Once a lead candidate is identified, clients are guided through the IND process with strategies and plans for the selection of appropriate CROs to support nonclinical studies.

Busby Pharma Consulting recognizes the growing importance of modeling in drug development, especially in relation to predictive pharmacokinetic and pharmacodynamic analysis. BPC works with clients to discuss which models and methodologies are useful at each stage of drug development and when a model specialist may be needed to shed light on the most effective options for their modeling needs.

We Provide A Fit-For-Purpose Approach To Discovery And Early Development Needs Of Small Companies, Offering Strategic And Operational Consulting Services Tailored To Their Unique Situation

As development progresses to clinical trials, Busby Pharma Consulting moves focus to crucial elements such as ADME studies, drug-drug interaction assessments, and clinical pharmacology. BPC actively collaborates with nonclinical and clinical teams, providing support in method development, result analysis, and report editing, and assists in preparing essential IND summaries for the FDA, Investigational Medicinal Product Dossiers (IMPD) for international trials, and briefing documents for regulatory meetings.

Building Organizational Growth for Clinical Development

Distinguishing Busby Pharma Consulting is its ability to go beyond the initial engagement and anticipate future drug development challenges. BPC offers comprehensive services like gap analysis and long-term vision for organizational growth. Its services encompass strategic planning and hands-on operational support, contributing to effective project implementation and execution. BPC helps clients identify and address potential gaps within their IND teams by carefully assessing the expertise required for successful execution.

BPC aids clients to evaluate if and when external expertise is required and explores options to augment teams, including additional consultants, outsourcing work to CROs or long-term hiring strategies. Some clients have asked Dr. Busby to become actively involved in their recruitment processes, aiding in interviewing potential candidates for key positions. This proactive approach ensures smooth scaling of operations when transitioning from early-stage research to clinical development.

“We have a track record of successfully transitioning companies from proof of concept in the laboratory to proof of concept in the clinical setting,” says Dr. Busby.

Given his wealth of experience in guiding preclinical startups to become successful clinical-stage companies, Dr. Busby has been asked to take on the role of acting head of pharmacokinetics, drug metabolism, and/or clinical pharmacology departments for clients. This leadership integration enables the consultancy to comprehensively understand the client’s goals and facilitate short-term and long-term planning for success.

BPCs advocacy extends to ensuring adequate cross-functional representation in crucial decision-making sessions to optimize efficiency. The approach also involves an evaluation of the client’s current quality frameworks and assistance in implementing relevant technologies, instrumentation, or external services, like CROs tailored to the project’s requirements.

Unraveling a Metabolic Puzzle

Busby Pharma Consulting’s worth in real-world applications of drug development was brought to the fore in its collaboration with Neurogastrx, a company developing a drug product for a new indication in the US using the active ingredient from a drug approved in France.

Despite being approved, the molecule lacked comprehensive information on its metabolism due to the absence of modern metabolism guidances during its original development over 40 years ago.

This drug had a major metabolite that accounted for over 80 percent of circulating material in blood. Neurogastrx approached Busby Pharma Consulting to understand the metabolic pathway and establish a clear drug-drug interaction (DDI) strategy.

For over nine months, Dr. Busby, along with other external collaborators, embarked on an intensive research and analysis journey, leading to a surprising discovery. They identified a highly unusual liver amidase enzyme responsible for metabolizing the molecule—an exceptional finding considering its rarity in small molecule drug metabolism.

The results of this significant research were eventually published, with Dr. Busby as the lead author, shedding light on an understudied area and the role of this enzyme in the molecule’s metabolism. Solving this mystery provided valuable insights that demonstrated there were minimal DDI risks and streamlined the company’s development plans.

Beyond addressing immediate concerns, the investigation led to an exciting discovery, highlighting the enzyme’s characteristics and contributing to broader scientific knowledge in the field of drug metabolism.

Anticipating and Mitigating Regulatory Hurdles

Over the past decade, Dr. Busby has dedicated himself to delivering valuable consulting services for small-scale pharmaceutical enterprises. He proactively engages with regulatory agencies during the development process. To stay ahead of industry changes, he prioritizes staying informed about the latest regulatory guidance changes. This includes connecting with colleagues in the regulatory field as well as closely monitoring FDA announcements and European regulatory developments for updates to preliminary and final guidelines that impact the drug development and approval processes. This ensures that his company remains well-informed of emerging issues and forthcoming changes for the benefit of client projects, boosting their confidence and success in navigating the complex regulatory landscape.

Busby Pharma Consulting believes clear and efficient scientific communication, (written and oral) is essential for successful drug discovery and development. It is important for effective cross-functional scientific teams, keeping upper management appropriately informed, and particularly critical when interacting with regulatory authorities. Whether a client is submitting an IND, IMPD, NDA, a protocol amendment, or a meeting request, asking or answering the right questions in a clear and concise way can greatly influence the outcome and is a critical service BPC provides.

A committed ally in guiding small-scale pharmaceutical enterprises from inception to fruition, Busby Pharma Consulting’s customized strategies continue to guarantee successful drug development. Amid funding challenges and regulatory complexities, it stands as a pillar of excellence in biopharma, helping clients bring their novel products to market.